Racura Oncology Ltd
Company Profile
Business description
Racura Oncology Ltdis a Phase 3 clinical biopharmaceutical company with a dedicated mission to be at the heart of cancer care. Racura's primary asset, RCDS1 (E,E-bisantrene), is a small molecule anticancer agent that functions by binding to G4-DNA and RNA, resulting to potent inhibition of the important cancer growth regulator MYC. RCDS1 has demonstrated therapeutic activity in cancer patients with a well characterised safety profile. Recent researchs made by the company have enabled composition of matter IP filings that provide for 20 years of patent protection over RCDS1. Racura is advancing a proprietary formulation of RCDS1 (RC220) to address the high unmet needs of patients across multiple oncology indications.
Contact
1 Macquarie Place
Level 36
Gateway
SydneyNSW2000
AUST: +61 280513043
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.90 | 57.30 | -0.62% |
| CAC 40 | 8,274.57 | 53.29 | -0.64% |
| DAX 40 | 24,066.70 | 22.48 | 0.09% |
| Dow JONES (US) | 48,463.72 | 72.27 | -0.15% |
| FTSE 100 | 10,559.58 | 49.48 | -0.47% |
| HKSE | 26,306.55 | 359.23 | 1.38% |
| NASDAQ | 24,016.02 | 376.94 | 1.59% |
| Nikkei 225 | 59,395.29 | 1,261.05 | 2.17% |
| NZX 50 Index | 13,068.96 | 7.62 | -0.06% |
| S&P 500 | 7,022.95 | 55.57 | 0.80% |
| S&P/ASX 200 | 8,948.70 | 68.50 | -0.76% |
| SSE Composite Index | 4,048.64 | 21.43 | 0.53% |